Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × OTHER × TP protocol × Clear all

Phase

Status

Unknown 9 Terminated 5 Completed 5 Recruiting 4 Not yet recruiting 3 Active not recruiting 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Squamous Cell Carcinoma 1

Interventions

Radiotherapy 76 pembrolizumab 69 Cyclophosphamide 61 Cisplatin 55 Magnetic Resonance Spectroscopy 50 Gemcitabine 47 Radiosurgery 45 Nivolumab 42 Carboplatin 41 Paclitaxel 40 Fluorouracil 36 Dexamethasone 34 Biopsy 34 Bevacizumab 31 Oxaliplatin 30 Docetaxel 30 fludarabine 29 Radiation 29 Surveys and Questionnaires 28 Leucovorin 28 Capecitabine 28 durvalumab 27 Melphalan 25 Rituximab 24 Irinotecan 24 fludarabine phosphate 23 Cytarabine 23 Lenalidomide 22 Doxorubicin 22 Etoposide 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04625543 2022-04-26

Neoadjuvant Immunotherapy to ESCC

Qilu Hospital of Shandong University

Phase 2 Withdrawn

Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡